LALPATHLAB - Dr. Lal Pathlabs Limited Share Price

Healthcare Services

₹2840.00+14.80(+0.52%)

Market Open as of Apr 28, 2025, 13:27 IST

What does Dr. Lal Pathlabs Limited do?

Healthcare Service Provider•Healthcare•Small Cap

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India.

Industry Group:Healthcare Services

Employees:4,099

Website:www.lalpathlabs.com

Summary of Latest Earnings Report from Dr. Lal Pathlabs

Summary of Dr. Lal Pathlabs's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated: Feb 25

Management Outlook:
Dr. Lal PathLabs anticipates sustained growth driven by strategic geographic and test mix optimization, digital/AI innovation, and expansion into Tier-2/3/4 markets. Emphasis on preventive diagnostics (via Swasthfit bundles) and personalized genomics (Genevolve) is expected to capitalize on rising NCDs. The company aims to maintain margins without price hikes, relying on operational efficiency and franchisee-led expansion (45% contribution).

Key Points:

Growth Drivers:
- Swasthfit: 27% YoY growth in Q3; plans to expand bundled test offerings.
- Geographic Expansion: 15"“20 new labs in FY25, focusing on underserved Tier-3/4 markets (North, East) and clusters in South/West.
- Digital Infrastructure: AI-enabled diagnostics and seamless patient experience via tech platforms.
Operational Metrics:
- Q3 revenue: Rs.597 Cr (+10.7% YoY); EBITDA margin: 25.8%.
- Patient volume growth: 3.8% YoY; test-per-patient up 6.3% (mix-driven).
Margins & Costs:
- Stable gross margins despite reagent cost pressures; no near-term price hikes.
- Employee costs up mid-teens due to sales/marketing hires and lab expansions.
Regional Focus:
- Delhi NCR and West outperformed; South prioritized for growth (organic/inorganic).
Dividend & Cash Position: Third interim dividend of Rs.6/share declared; net cash Rs.1,123 Cr as of Dec 2024.
Challenges: Competitive intensity in metros; forex/import cost risks.

Forward Strategy: Balance metro/Tier-1 presence with Tier-3/4 penetration while leveraging Swasthfit, genomics, and radiology adjacencies for long-term growth.

Q&A Session

Last updated: Feb 25

Question 1: Can you elaborate on the factors driving gross margin improvement despite no price increases, and the reasons behind the mid-teens growth in employee expenses?
Answer: Gross margins slightly declined YoY. Employee expenses rose due to hiring for new infrastructure and sales teams. Future gross margins are expected to stabilize, with ongoing investments in organic expansion.

Question 2: Why are depreciation/amortization figures flat, and what is the tax rate outlook?
Answer: Depreciation remains stable due to limited recent CAPEX. The effective tax rate (29%) accounts for adjustments like non-tax-deductible depreciation; the standalone rate is 25%, with no expected changes.

Question 3: What is the medium-term revenue contribution target for Swasthfit, and how will it scale?
Answer: Swasthfit contribution rises seasonally (peaking in Q4) and grows ~27% YoY. Bundled tests align with preventive healthcare trends, aiming for higher penetration in Tier-3/4 markets.

Question 4: Why did Suburban's revenue underperform, and what are FY26 plans?
Answer: Suburban's Q3 softness reflects quarterly volatility. Focus remains on overall West region growth, leveraging shared infrastructure across brands (Suburban, Dr. Lal, PathLabs Unifiers).

Question 5: Could domestic reagent adoption improve gross margins?
Answer: Domestic sourcing provides partial relief, but currency inflation and reagent costs pressure margins. No significant gross margin expansion is anticipated.

Question 6: Why did Swasthfit's revenue contribution dip to 23% in Q3?
Answer: Contribution fluctuates seasonally (e.g., tax-driven Q4 surges). YoY growth (27%) remains robust, with long-term potential tied to rising NCD testing demand.

Question 7: What were Suburban's EBITDA margins and the tax rate rationale?
Answer: Suburban's Q3 EBITDA margin improved to 12.3% YoY (vs. 11.5%). Higher consolidated tax rate (29%) stems from non-deductible costs; standalone tax rate is 25%.

Question 8: Are smaller labs consolidating, and is a price hike planned?
Answer: Industry stability reduces unorganized competition. No immediate price hikes; focus on volume growth. Competitors' increases may benefit smaller labs.

Question 9: What metrics define lab/collection center productivity?
Answer: Franchisee-led collection centers (45% contribution) lower fixed costs. No fixed lab-to-center ratio; optimization balances turnaround time and cost efficiency.

Question 10: How does hospital competition impact Delhi NCR pricing?
Answer: Hospitals prioritize infrastructure over pricing aggression. Organized competition aids market shift from unorganized players.

Question 11: Which regions drive growth, and where are margins highest?
Answer: All regions except South align with national averages. Margins rank: Delhi NCR > North > East/West. South is a focus for expansion.

Question 12: What savings will Suburban's liquidation bring?
Answer: Administrative/legal cost reductions are expected but not material.

Question 13: How many labs were added in 9M FY25, and is Delhi's growth organic?
Answer: 15"“20 labs planned FY25; Delhi's growth is primarily same-store.

Question 14: Are adjacent segments (e.g., radiology, genomics) part of M&A strategy?
Answer: Genomics (via Genevolve) and basic radiology (ultrasound/X-ray) are organic adjacencies. M&A focuses on geography, not capabilities.

Question 15: What is the patient volume outlook and franchisee mix trend?
Answer: YTD patient volume grew 4.4%. Franchisee contribution (~45%) is stabilizing, supplemented by pickup points (20"“25%).

Question 16: How does Swasthfit compete with discounted bundles?
Answer: Industry-wide bundling expands the category; online players drive awareness, benefiting all organized players.

Question 17: What are West/South expansion plans?
Answer: South (Chennai, Bangalore, Hyderabad) is a priority for organic/inorganic growth. West contributes ~15% of revenue.

Question 18: Will M&A target new testing capabilities?
Answer: High-end tests (genomics, autoimmune) require equipment/operational investment, not acquisitions.

Question 19: Can volume growth revert to pre-COVID levels?
Answer: Targeting pre-COVID patient volume growth (7"“8%) via geographic expansion, balancing sample growth from bundling.

Question 20: Will metro lab expansion accelerate volume growth?
Answer: Metro/Tier-1 investments target underserved demand, complementing Tier-3/4 growth to boost patient and sample volumes.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Sector Comparison: LALPATHLAB vs Healthcare Services

Comprehensive comparison against sector averages

Comparative Metrics

LALPATHLAB metrics compared to Healthcare

Category	LALPATHLAB	Healthcare
PE	55.89	64.54
PS	9.48	7.07
Growth	11.3 %	4.9 %

Performance Comparison

LALPATHLAB vs Healthcare (2021 - 2025)

Key Insights

1. LALPATHLAB is among the Top 3 Healthcare Service Provider companies by market cap.
2. The company holds a market share of 33.9% in Healthcare Service Provider.
3. In last one year, the company has had an above average growth that other Healthcare Service Provider companies.

Share Holdings

Understand Dr. Lal Pathlabs ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

As of 2025-03-31

Shareholder Name	Holding %
Arvind Lal	30.8%
Vandana Lal	19.24%
Invesco Oppenheimer International Growth Fund	3.52%
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund	3.23%
Uti-Flexi Cap Fund	2.32%
Anjaneya Lal	2.02%
Archana Lal Erdmann	1.85%
Sbi Large & Midcap Fund	1.7%
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund	1.68%
Smallcap World Fund, Inc	1.47%
Life Insurance Corporation of India	1.47%
The Brown Capital Management International Small Company Fund	1.34%
Indus India Fund (Mauritius) Limited	1.02%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Income Statement for Dr. Lal Pathlabs

Standalone figures (in Rs. Crores) / View Consolidated Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	-9.6%	528	584	534	479	476	532
Other Income	38.1%	30	22	29	16	15	14
Total Income	-7.9%	558	606	563	495	491	546
Cost of Materials	-7.3%	102	110	105	95	93	104
Employee Expense	2.8%	110	107	101	90	93	90
Finance costs	-5%	4.8	5	5.5	5.9	6.5	7.1
Depreciation and Amortization	5.9%	19	18	18	20	19	19
Other expenses	-6.1%	171	182	173	164	160	174
Total Expenses	-4%	406	423	402	374	372	395
Profit Before exceptional items and Tax	-17.6%	151	183	161	120	120	151
Total profit before tax	-17.6%	151	183	161	120	120	151
Current tax	-18.6%	36	44	40	30	32	40
Deferred tax	-127.6%	0.2	3.9	-2.4	1	-0.7	-1.9
Total tax	-23.4%	37	48	38	31	31	38
Total profit (loss) for period	-15.7%	114	135	123	90	88	113
Other comp. income net of taxes	42.9%	-0.2	-1.1	-0.1	-0.4	0	-0.4
Total Comprehensive Income	-15%	114	134	123	89	88	113
Earnings Per Share, Basic	-16.4%	13.74	16.24	14.76	10.73	10.78	13.6
Earnings Per Share, Diluted	-16.4%	13.71	16.2	14.73	10.71	10.75	13.57

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	11.2%	1,967	1,769	1,873	1,490	1,274	1,165
Other Income	28.3%	60	47	53	51	58	46
Total Income	11.6%	2,027	1,816	1,926	1,542	1,331	1,211
Cost of Materials	0.3%	391	390	446	374	287	255
Employee Expense	15.2%	364	316	320	257	232	202
Finance costs	-21.2%	27	34	28	15	15	0.7
Depreciation and Amortization	-7.4%	76	82	75	70	68	36
Other expenses	8.3%	653	603	596	452	427	425
Total Expenses	6%	1,511	1,425	1,466	1,168	1,028	919
Profit Before exceptional items and Tax	32.1%	516	391	459	374	303	292
Total profit before tax	32.1%	516	391	459	374	303	292
Current tax	37%	138	101	118	98	80	100
Deferred tax	-75%	-6	-3	-2.7	-4.5	-0.7	-3.6
Total tax	35.1%	132	98	115	94	80	97
Total profit (loss) for period	31.6%	384	292	344	280	223	195
Other comp. income net of taxes	-244.4%	-0.3	1.9	-1.3	-0.7	-1.1	-1.9
Total Comprehensive Income	30.7%	384	294	343	279	222	194
Earnings Per Share, Basic	32%	46.25	35.28	41.61	33.93	27.09	23.74
Earnings Per Share, Diluted	32.2%	46.18	35.17	41.48	33.85	27.04	23.69

Consolidated figures (in Rs. Crores) / View Standalone Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	-9.6%	597	660	602	545	539	601
Other Income	14.3%	25	22	21	18	18	18
Total Income	-8.8%	622	682	622	564	557	619
Cost of Materials	-7.9%	117	127	119	109	107	122
Employee Expense	1.6%	126	124	117	105	109	105
Finance costs	-14%	5.3	6	6	6.6	7	7.8
Depreciation and Amortization	2.9%	36	35	35	37	36	36
Other expenses	-3.4%	199	206	196	186	182	196
Total Expenses	-3%	484	499	473	444	441	467
Profit Before exceptional items and Tax	-24.7%	138	183	150	120	116	152
Total profit before tax	-24.7%	138	183	150	120	116	152
Current tax	-17%	40	48	45	33	34	43
Deferred tax	-110.3%	0.7	3.9	-2.7	1.5	-0.7	-1.6
Total tax	-23.5%	40	52	42	34	34	42
Total profit (loss) for period	-25.4%	98	131	108	86	82	111
Other comp. income net of taxes	38.9%	-0.1	-0.8	-0.1	-0.9	0.2	-0.1
Total Comprehensive Income	-24.8%	98	130	108	85	82	111
Earnings Per Share, Basic	-27%	11.6	15.52	12.79	10.13	9.77	13.16
Earnings Per Share, Diluted	-26.9%	11.58	15.48	12.76	10.12	9.76	13.12

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	10.4%	2,227	2,017	2,087	1,581	1,330	1,203
Other Income	65.9%	69	42	52	51	55	46
Total Income	11.5%	2,296	2,059	2,140	1,633	1,385	1,249
Cost of Materials	0.9%	451	447	502	397	299	262
Employee Expense	12.8%	424	376	365	274	243	208
Finance costs	-24.3%	29	38	30	16	15	0.8
Depreciation and Amortization	-4%	144	150	108	77	73	38
Other expenses	5.4%	741	703	660	474	446	439
Total Expenses	4.4%	1,790	1,715	1,665	1,238	1,075	949
Profit Before exceptional items and Tax	47.2%	506	344	475	394	310	301
Total profit before tax	47.2%	506	344	475	394	310	301
Current tax	37.4%	148	108	126	102	84	104
Deferred tax	4.9%	-4.8	-5.1	-1.9	-4.2	-0.9	-3.5
Total tax	39.2%	143	103	125	98	83	100
Total profit (loss) for period	50.4%	362	241	350	296	228	200
Other comp. income net of taxes	-366.7%	-0.6	1.6	-1.3	-0.8	-1.1	-2
Total Comprehensive Income	49.2%	362	243	349	296	226	198
Earnings Per Share, Basic	51.2%	43.05	28.82	41.7	35.33	27.42	24.19
Earnings Per Share, Diluted	51.3%	42.98	28.74	41.57	35.25	27.37	24.15

Investor Care
Dividend Yield	1.27%
Dividend/Share (TTM)	36
Shares Dilution (1Y)	0.13%
Diluted EPS (TTM)	49.94

Financial Health
Current Ratio	2.87
Debt/Equity	0.02
Debt/Cashflow	12.84

Valuation
Market Cap	23.62 kCr
Price/Earnings (Trailing)	55.89
Price/Sales (Trailing)	9.48
EV/EBITDA	31.19
Price/Free Cashflow	51.04
MarketCap/EBT	39.94

Fundamentals
Revenue (TTM)	2.49 kCr
Rev. Growth (Yr)	11.59%
Rev. Growth (Qtr)	-8.84%
Earnings (TTM)	422.5 Cr
Earnings Growth (Yr)	19.34%
Earnings Growth (Qtr)	-25%

Profitability
Operating Margin	23.74%
EBT Margin	23.74%
Return on Equity	20.76%
Return on Assets	16.27%
Free Cashflow Yield	1.96%

Balance Sheet for Dr. Lal Pathlabs

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	-82.5%	58	326	89	220	21	349
Current investments	189.9%	201	70	93	141	96	0
Loans, current	-200%	0.8	1.2	1	1.2	0.9	0.9
Total current financial assets	20%	1,049	874	839	772	607	641
Inventories	33.3%	37	28	32	23	41	40
Current tax assets	-	0	0	0	0	0	18
Total current assets	21%	1,113	920	892	810	660	714
Property, plant and equipment	-4.1%	282	294	296	345	357	351
Capital work-in-progress	-86.7%	1.4	4	9.7	3	6.6	14
Investment property	0%	34	34	34	0	0	0
Goodwill	0%	1.1	1.1	1.1	1.1	1.1	1.1
Non-current investments	0%	1,073	1,073	1,072	1,072	1,079	1,069
Loans, non-current	-	0	0	0	0.1	0.1	0.1
Total non-current financial assets	-1%	1,082	1,093	1,086	1,097	1,102	1,084
Total non-current assets	-1.9%	1,466	1,495	1,500	1,510	1,544	1,500
Total assets	6.8%	2,579	2,415	2,392	2,320	2,204	2,214
Borrowings, non-current	-	0	0	42	83	125	167
Total non-current financial liabilities	-5.6%	86	91	152	198	248	288
Total non-current liabilities	-5.6%	86	91	152	198	248	288
Borrowings, current	-50%	42	83	83	153	112	179
Total current financial liabilities	-4.3%	334	349	345	380	351	398
Provisions, current	-30%	22	31	27	23	20	20
Current tax liabilities	133.3%	29	13	25	0.5	14	3
Total current liabilities	-1.2%	419	424	430	432	410	450
Total liabilities	-2.1%	505	516	582	630	657	738
Equity share capital	0%	84	84	84	83	83	83
Total equity	9.2%	2,074	1,900	1,810	1,690	1,547	1,476
Total equity and liabilities	6.8%	2,579	2,415	2,392	2,320	2,204	2,214

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	-70.6%	107	361	120	264	51	378
Current investments	154.9%	289	114	110	150	124	66
Loans, current	-100%	1	1.3	1.2	1.4	1.1	1.1
Total current financial assets	17%	1,252	1,070	1,016	923	766	804
Inventories	27.8%	47	37	41	34	54	52
Current tax assets	-	0	0	0	0	0	25
Total current assets	17.7%	1,326	1,127	1,079	973	835	900
Property, plant and equipment	-4.4%	328	343	347	401	416	415
Capital work-in-progress	-86.7%	1.4	4	9.8	3	6.6	14
Investment property	0%	34	34	34	0	0	0
Goodwill	0%	548	548	548	548	555	550
Loans, non-current	-	0	0	0	0.1	0.1	0.1
Total non-current financial assets	-19.4%	26	32	25	40	31	24
Total non-current assets	-4.3%	1,272	1,329	1,366	1,412	1,467	1,453
Total assets	5.8%	2,598	2,456	2,445	2,386	2,302	2,353
Borrowings, non-current	-	0	0	42	83	125	167
Total non-current financial liabilities	-5.9%	97	103	165	213	266	306
Total non-current liabilities	-4.8%	100	105	168	216	269	310
Borrowings, current	-50%	42	83	83	153	112	179
Total current financial liabilities	-3.2%	367	379	376	409	382	435
Provisions, current	-21.6%	30	38	33	29	26	27
Current tax liabilities	133.3%	29	13	25	0.5	14	3.1
Total current liabilities	-0.6%	462	465	471	470	450	500
Total liabilities	-1.6%	562	571	639	686	719	810
Equity share capital	0%	84	84	84	83	83	83
Non controlling interest	-5.7%	34	36	34	33	33	36
Total equity	8%	2,035	1,885	1,806	1,700	1,583	1,544
Total equity and liabilities	5.8%	2,598	2,456	2,445	2,386	2,302	2,353

Cash Flow for Dr. Lal Pathlabs

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	-21.2%	27	34	28
Change in inventories	-134.7%	-4.2	16	-0.8
Depreciation	-7.4%	76	82	75
Impairment loss / reversal	-300%	0	1.5	1.1
Dividend income	-80%	3.2	12	1.6
Adjustments for interest income	63%	45	28	45
Share-based payments	0%	21	21	32
Net Cashflows from Operations	14.4%	603	527	541
Income taxes paid (refund)	26.5%	125	99	117
Net Cashflows From Operating Activities	11.7%	478	428	424
Cashflows used in obtaining control of subsidiaries	-101%	0.8	22	942
Proceeds from sales of PPE	-	0.8	0	0.4
Purchase of property, plant and equipment	41.9%	45	32	63
Proceeds from sales of investment property	-11.1%	0	0.1	0
Purchase of intangible assets	-35.8%	4.4	6.3	5.5
Dividends received	-80%	3.2	12	1.6
Interest received	34.6%	36	27	48
Other inflows (outflows) of cash	115.2%	42	-268.1	460
Net Cashflows From Investing Activities	110.7%	32	-288.6	-448.5
Proceeds from exercise of stock options	2600%	3.5	0.9	0.1
Proceeds from borrowings	-	0	0	345
Repayments of borrowings	40.7%	153	109	0
Payments of lease liabilities	50%	28	19	59
Dividends paid	103.1%	200	99	116
Interest paid	-39.5%	27	44	28
Other inflows (outflows) of cash	-11.1%	0	0.1	0
Net Cashflows from Financing Activities	-49.4%	-403.9	-270	142
Net change in cash and cash eq.	179.5%	106	-131	117

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	-24.3%	29	38	30
Change in inventories	-125%	-3.5	19	-10
Depreciation	-4%	144	150	108
Impairment loss / reversal	-115.2%	0	7.6	-1.3
Unrealised forex losses/gains	14.3%	-0.2	-0.4	0
Adjustments for interest income	68.8%	55	33	47
Share-based payments	-4.5%	22	23	32
Net Cashflows from Operations	18.7%	667	562	577
Income taxes paid (refund)	24.8%	132	106	130
Net Cashflows From Operating Activities	17.4%	535	456	447
Cashflows used in obtaining control of subsidiaries	-	0.4	0	458
Proceeds from sales of PPE	80%	0.9	0.5	1.6
Purchase of property, plant and equipment	42.9%	51	36	94
Purchase of intangible assets	-25.4%	6.3	8.1	382
Interest received	46.7%	45	31	50
Other inflows (outflows) of cash	94.7%	-12.6	-256	436
Net Cashflows From Investing Activities	91.2%	-24.3	-287.3	-449.2
Proceeds from issuing shares	-900%	0	0.9	0
Proceeds from exercise of stock options	-	3.5	0	0.2
Proceeds from borrowings	-	0	0	345
Repayments of borrowings	40.7%	153	109	0
Payments of lease liabilities	0%	34	34	62
Dividends paid	96.1%	201	103	117
Interest paid	-24.3%	29	38	30
Other inflows (outflows) of cash	9.1%	0	-0.1	0
Net Cashflows from Financing Activities	-46%	-413.9	-283.2	136
Net change in cash and cash eq.	183.1%	97	-114.5	134

Is Dr. Lal Pathlabs Better than it's peers?

Detailed comparison of Dr. Lal Pathlabs against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
APOLLOHOSP	Apollo Hospitals EnterprisesHospital	99.74 kCr	21.31 kCr	+6.39%	+8.65%	73.93	4.68	+15.13%	+64.06%
FORTIS	Fortis HealthcareHospital	49.42 kCr	7.62 kCr	+1.39%	+47.16%	59.94	6.49	+12.17%	+42.06%
VIJAYA	Vijaya Diagnostic CentreHealthcare Service Provider	10.66 kCr	679.37 Cr	+3.34%	+50.19%	74.73	15.69	+26.82%	+25.44%
METROPOLIS	Metropolis HealthcareHealthcare Service Provider	8.99 kCr	1.33 kCr	+11.02%	-1.05%	58.82	6.77	+13.76%	+21.84%
THYROCARE	Thyrocare TechHealthcare Service Provider	4.78 kCr	668.16 Cr	+25.81%	+36.75%	44.6	7.16	+18.66%	+65.42%

LALPATHLAB - Dr. Lal Pathlabs Limited Share Price

What does Dr. Lal Pathlabs Limited do?

Summary of Latest Earnings Report from Dr. Lal Pathlabs

Sector Comparison: LALPATHLAB vs Healthcare Services

Comparative Metrics

Performance Comparison

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Income Statement for Dr. Lal Pathlabs

Investor Care

Financial Health

Valuation

Fundamentals

Profitability

Balance Sheet for Dr. Lal Pathlabs

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Cash Flow for Dr. Lal Pathlabs

Is Dr. Lal Pathlabs Better than it's peers?